LDL and HDL Subfractions, Dysfunctional HDL: Treatment Options

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|20|40|6249-6255

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.40, 2014-12, pp. : 6249-6255

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Subfractions and Subpopulations of HDL: An Update

By  

Current Medicinal Chemistry, Vol. 21, Iss. 25, 2014-08 ,pp. : 2881-2891

Bentham Science Publishers

Access to resources Recommend Favorite

Identifying and Attaining LDL-C Goals: Mission Accomplished? Next Target: New Therapeutic Options to Raise HDL-C Levels

By  

Current Drug Targets, Vol. 8, Iss. 3, 2007-01 ,pp. : 483-488

Bentham Science Publishers

Access to resources Recommend Favorite

The clinical impact of pitavastatin: comparative studies with other statins on LDL-C and HDL-C

By Teramoto Tamio  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 6, 2012-04 ,pp. : 859-865

Informa Healthcare

Access to resources Recommend Favorite

Pathophysiological Role and Clinical Significance of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Bound to LDL and HDL

By  

Current Pharmaceutical Design, Vol. 20, Iss. 40, 2014-12 ,pp. : 6256-6269

Bentham Science Publishers

Access to resources Recommend Favorite

Paradoxically, serum HDL-cholesterol levels are lowered by concomitant treatment with fenofibrate and rosiglitazone

By  

Reactions Weekly, Vol. 1, Iss. 1019, 2004-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite